Knowledge, awareness, approach and management of vulvo-vaginal infections with topical combination preparations: A cross-sectional, questionnaire based gynaecologists survey

Authors : Archana Karadkhele, Gaurav Puppalwar, Manish R Pandya, Rishi Jain

DOI : 10.18231/j.ijogr.2020.044

Volume : 7

Issue : 2

Year : 2020

Page No : 210-215

Background: Vulvo-vaginal infection (VVI) often results in abnormal vaginal discharge, soreness,
redness and pain during urination. As per CDC 2017, vulvovaginitis is a second common infection. For
management of VVI, both oral and topical preparations are available. But, there is scarcity of data on
prevalent clinical practices in the management of VVI in India.
Materials and Methods: This cross-sectional, non-interventional, observational, multicentric,
questionnaire based survey was conducted with 992 gynaecologists across India. A series of 10 multiple
choice questions were prepared. The questionnaire was targeted on prevalent practices in topical
management of patients with VVI. All the parameters were summarized using descriptive statistics.
Results: Majority of the gynaecologists (N=772/992, 78%) in the survey responded that they treat
approximately 10 patients with VVI per week. About 54% of gynaecologists (N=532/992) consider pH of
the topical preparation as an important parameter. Nearly, 82% of gynaecologists (N=818/992) prefer using
a lower potency steroid like mometasone for application on genital areas instead of higher potency steroid
like clobetasol. About 98% of gynaecologists were satisfied (67%; N=664/992) to very satisfied (31%;
N=312/992) with the use of triple drug topical combination of nadifloxacin, terbinafine and mometasone in
the management of VVI.
Conclusion: This survey concluded that VVI is commonly seen in gynaecological practice in India.
Further more, triple drug topical combination of antibiotic, antifungal and steroid is generally preferred
by gynaecologists in the management of VVI with satisfactory results.

Keywords: Vulvo-vaginal infection, Nadifloxacin, Terbinafine, Mometasone.


Citation Data


Related Articles